Cargando…

The Treatment of Activated PI3Kδ Syndrome

Activated phosphoinositide 3-kinase δ syndrome (APDS), also known as PASLI disease (p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency) are combined immunodeficiencies resulting from gain-of-function mutations in the genes (PIK3CD and PIK3R1) encoding the subu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coulter, Tanya I., Cant, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137162/ https://www.ncbi.nlm.nih.gov/pubmed/30245694 http://dx.doi.org/10.3389/fimmu.2018.02043

Ejemplares similares

Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment
por: Vanselow, Sven, et al.
Publicado: (2023)

Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes
por: Redenbaugh, Vyanka, et al.
Publicado: (2021)

Epstein–Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency
por: Carpier, Jean-Marie, et al.
Publicado: (2018)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome
por: Asano, Takaki, et al.
Publicado: (2018)

Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2
por: Hong, Ying, et al.
Publicado: (2019)

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry
por: Maccari, Maria Elena, et al.
Publicado: (2018)

PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19
por: Palma, Giuseppe, et al.
Publicado: (2020)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome
por: Cohen, Jeffrey I.
Publicado: (2018)

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8(+) T Cells
por: Bowers, Jacob S., et al.
Publicado: (2017)

Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3Kδ
por: Cevey, Ágata C., et al.
Publicado: (2021)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies
por: Haselmayer, Philipp, et al.
Publicado: (2014)

PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4(+) T Cells
por: Luff, Daisy H., et al.
Publicado: (2021)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

Epidermodysplasia verruciformis in a young adult with activated PI3Kδ syndrome
por: Donaldson, Stephanie L., et al.
Publicado: (2019)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome
por: Thauland, Timothy J., et al.
Publicado: (2019)

PI3K in T Cell Adhesion and Trafficking
por: Johansen, Kristoffer H., et al.
Publicado: (2021)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Inhibition of PI3Kδ Enhances Poly I:C-Induced Antiviral Responses and Inhibits Replication of Human Metapneumovirus in Murine Lungs and Human Bronchial Epithelial Cells
por: Fujita, Akitaka, et al.
Publicado: (2020)

Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome
por: Yin, Zexi, et al.
Publicado: (2021)

PI3Kδ is indispensable for CTL-mediated cytotoxicity
por: Putz, Eva M, et al.
Publicado: (2011)

Editorial: Human Disorders of PI3K Biology
por: Lucas, Carrie L., et al.
Publicado: (2020)

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials
por: Wang, Zhongwang, et al.
Publicado: (2023)

Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases
por: Ghorbanalipoor, Saeedeh, et al.
Publicado: (2022)

Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects
por: Jhamnani, Rekha D., et al.
Publicado: (2018)

Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model
por: Serra, Ines, et al.
Publicado: (2021)

Inhibition of PI3Kδ Differentially Regulates Poly I:C– and Human Metapneumovirus–Induced PD–L1 and PD–L2 Expression in Human Bronchial Epithelial Cells
por: Ogawa, Tomohiro, et al.
Publicado: (2021)

Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies
por: Karanovic, Djuro, et al.
Publicado: (2019)

PI3K Signaling in B Cell and T Cell Biology
por: Okkenhaug, Klaus, et al.
Publicado: (2014)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy
por: Michalovich, David, et al.
Publicado: (2018)

Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases
por: Ghorbanalipoor, Saeedeh, et al.
Publicado: (2022)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

PI3Kδ过度活化综合征一例
Publicado: (2021)

Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2
por: Nguyen, Tina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gb8cg5f5rg53ghbpdtb5j3rtm0